This page uses content from Wikipedia and is licensed under CC BY-SA.
Tetrabamate ( Atrium, G Tril, Sevrium) is a combination drug formulation of febarbamate, difebarbamate, and phenobarbital which was marketed in France and Spain and was used to treat anxiety and alcohol withdrawal-associated muscle tremors, agitation, and depression.    It was largely, but not completely  discontinued on April 4, 1997 after over 30 years of use due to reports of hepatitis and acute liver failure.    The decision to restrict the use of the drug had been long-awaited. 
. Taylor & Francis US. 2000. pp. 333 & 427. Index nominum 2000: international drug directory ISBN 978-3-88763-075-1 . Retrieved . 26 November 2011
Eugene R. Schiff; Willis C. Maddrey; Michael F. Sorrell (19 October 2011). . John Wiley and Sons. p. 2276. Schiff's Diseases of the Liver ISBN 978-1-119-95048-6 . Retrieved . 26 November 2011
^ a b
Binder D, Jost R, Flury R, Salomon F (May 1995). "[Acute liver failure following tetrabamate]". Schweizerische Medizinische Wochenschrift (in German). 125 (19): 965–9. PMID 7761807.
^ a b
. United Nations Publications. 2003. p. 259. Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments ISBN 978-92-1-130230-1 . Retrieved . 26 November 2011
Horsmans Y, Lannes D, Pessayre D, Larrey D (December 1994). "Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate". Journal of Hepatology. 21 (6): 1075–9. doi: 10.1016/s0168-8278(05)80620-8. PMID 7699230.
^ a b
"Severe hepatitis due to Atrium". Prescrire International. 10 (55): 150. October 2001. PMID 11824432.